Pharmacoeconomic Analysis of Capecitabine versus 5-Fluorouracil/Leucovorin as Adjuvant Therapy for Stage III Colon Cancer in Taiwan
作者: Tzu-Chi HsuHong-Hwa ChenMing-Chin YangHwei-Ming WangJye-Hann ChuangShu-Wen JaoHsin-Chieh ChiangChung-Yu WenJen-Hao TsengLi-Tzong Chen
作者单位: 1Mackay Memorial Hospital and Taipei Medical University, Taipei, Taiwan
2Chang Gung Memorial Hospital—Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
3Department of Public Health and Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan
4Taichung Veterans General Hospital, Taichung, Taiwan
5Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
6Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan
7Department of Leisure and Tourism, Taipei College of Maritime Technology, Taipei, Taiwan
8Roche Products Ltd, Taipei, Taiwan
9National Institute of Cancer Research, National Health Research Institutes, Tainan,Taiwan
刊名: Value in Health, 2011, Vol.14 (5), pp.647-651
来源数据库: Elsevier Journal
DOI: 10.1016/j.jval.2011.01.010
关键词: 5-fluorouracil/leucovorinadjuvant therapycapecitabinecolon cancerpharmacoeconomics
原始语种摘要: Abstract(#br)Objectives(#br)To assess the cost-effectiveness of oral capecitabine compared with intravenous bolus 5-fluorouracil/leucovorin (5-FU/LV) in the adjuvant treatment of stage III colon cancer in Taiwan from payer (Bureau of National Health Insurance [BNHI]) perspectives.(#br)Methods(#br)A health state-transition model was developed to estimate the incremental costs and effectiveness of capecitabine versus 5-FU/LV. The time horizons studied were: treatment duration (24 weeks) plus 36 months, 48 months, 60 months, 120 months, and lifetime. Costs were expressed in Taiwanese new dollars (NT$). Clinical outcomes, medical resource use, and utilities were extracted from published sources. Unit costs were estimated from BNHI fee schedules, published sources, and local expert opinion....
全文获取路径: Elsevier  (合作)
影响因子:2.191 (2012)

  • costs 费用
  • estimate 估计
  • versus 
  • savings 储蓄
  • uncertainty 不定
  • Analysis 分析
  • lifetime 寿命
  • effectiveness 有效性
  • treatment 处理
  • National 国民牌大客车